NVIDIA Corporation rose 7.37% to $225.12 in premarket trading at 05:43 EDT. The move followed quarterly revenue that more than doubled and a forecast above Wall Street expectations.
| Metric | Current | Comparison |
|---|---|---|
| GAAP gross margin | 75.0% | 74.0% Q3 midpoint |
| GAAP operating income | $63.73bn | +124% Y/Y |
| Operating cash flow | $24.08bn | Q2 FY2027 |
| Accounts receivable | $63.06bn | +64% since Jan. 25 |
| Inventory | $31.58bn | +48% since Jan. 25 |
| Capital returned | $26.0bn | Q2 buybacks + dividends |
| Forward P/E | 17.9× |
| AMD forward P/E | 37.2× |
| Intel forward P/E | 46.2× |
| Analyst consensus | Buy · 61 analysts |
| Average target | $305.79 |
| Raymond James | Strong Buy · $352 |
| Metric | Latest figure | Growth / margin | Investor signal |
|---|---|---|---|
| Q2 2026 net sales | $5.442B | +7.5% reported | Growth exceeded Q3’s 3%–5% guide |
| Cardiovascular sales | $3.624B | +8.3% | 66.6% of Q2 revenue |
| MedSurg sales | $1.818B | +5.9% | 33.4% of Q2 revenue |
| Gross profit | $3.848B | 70.7% margin | Expedited freight or remediation could pressure margin |
| Adjusted EPS | $0.86 | FY guide $3.28–$3.32 | Guidance risk depends on restoration time |
| Market capitalization | $69.81B |
| Trailing P/E | 20.2× |
| Forward P/E | 15.2× |
| Enterprise value / revenue | 4.02× |
| Average analyst target | $62.69 |
| Implied upside to close | 30.1% |
The company has not identified the attacker, disclosed whether protected information was accessed, or estimated the financial impact. Longer disruption could add freight, remediation and support costs.
| Metric | Result | Year over year |
|---|---|---|
| Revenue | $570.6M | +1.7% |
| U.S. same-restaurant sales | — | −7.0% |
| U.S. systemwide sales | $2.88B | −8.2% |
| U.S. restaurant margin | 13.8% | −240 bps |
| Operating profit | $79.3M | −24.0% |
| Net income | $32.6M | −40.8% |
| H1 free cash flow | $120.3M | +9.9% |
FactSet current estimates on Aug. 26. One month earlier: $0.14, $0.57 and $0.64, respectively.
| Company | P/E | Consensus |
|---|---|---|
| Wendy’s | 13.7x | Hold |
| Restaurant Brands | 21.4x | Buy |
| Yum! Brands | 19.5x | Buy |
| Reference | Price | Distance |
|---|---|---|
| 52-week high · June 16 | $225.64 | −38.1% |
| Average analyst target | $220.20 | +57.7% |
| Aug. 26 close | $139.63 | Base |
| IPO price · June | $135.00 | +3.4% |
| 52-week low · Aug. 3 | $104.83 | +33.2% |
Louisiana expands Starship launch capacity for three revenue engines: external launch services, Starlink deployment and orbital AI infrastructure. The $100 billion headline equals all June liquidity and 3.5 times first-half capex.
Starship cadenceStarlink capacityAI satellitesNo annual spending schedule, financing plan or return target was disclosed. Starship reusability, permits, wetland mitigation and launch demand must advance before the campus can earn a return.
engineeringregulationcash burnenvironment| Checkpoint | Timing | What investors need |
|---|---|---|
| Phased budget | Not disclosed | Annual cash use, debt and partner funding |
| Permits and wetlands plan | Pre-construction | Schedule certainty and mitigation cost |
| Construction start | Expected 2027 | Evidence the plan is funded and active |
| Starship scale-up | Ongoing | Reliability, reusability and lower launch cost |
| First Louisiana launch | Targeted 2029 | Capacity begins supporting revenue channels |
Market snapshot: August 26, 2026, 19:49 EDT (August 27, 01:49 CEST). Regular-session figures unless noted.
+121.7% versus Wednesday's close
| Metric | Value | Growth |
|---|---|---|
| Total revenue | $67.4bn | +17% |
| Total cloud | $34.0bn | +39% |
| Cloud infrastructure | $18.1bn | +77% |
| Cloud applications | $15.9bn | +11% |
| RPO | $638bn | +363% |
RPO equals about 9.5 times annual revenue, but converts over several years.
| Operating cash flow | $32.0bn |
| Capital expenditure | −$55.7bn |
| Free cash flow | −$23.7bn |
| FY26 debt raised | $43bn |
| FY26 equity raised | $5bn |
| Planned FY27 financing | ≈$40bn |
Planned FY27 financing includes a previously announced $20bn at-the-market equity program.
| Company | Close | Daily move | Market value | P/E |
|---|---|---|---|---|
| Oracle | $148.87 | +2.84% | $433.5bn | 26.7× |
| Microsoft | $496.37 | +0.91% | $3.70tn | 29.5× |
| Alphabet | $342.00 | −1.40% | $4.18tn | 17.2× |
| SAP ADR | $211.68 | −2.45% | $247.1bn | — |
August 26 U.S. close; latest trade timestamps ranged from 19:15 to 19:38 EDT.
Average target across 39 analysts tracked by MarketBeat.
| Low | $145 |
| Average | $263.97 |
| High | $400 |
| Average implied upside | 77.3% |
Citi opened a positive 90-day catalyst watch. Oracle also held a financial analyst meeting at 10:45 CT.
Investors will test cloud-capacity delivery, financing costs and signs that the historic selloff is losing force.
| Risk | Investor transmission | Watch point |
|---|---|---|
| Build delays | Defers contracted revenue | Capacity delivery |
| Negative cash flow | Raises external-funding needs | Capex and OCF |
| Equity issuance | Dilutes existing holders | $20bn ATM program |
| Credit pressure | Increases financing costs | Spreads and ratings |
| Customer concentration | Raises contract and renewal sensitivity | RPO mix |
Sources: Oracle investor relations, Citi commentary reported August 26, Yahoo Finance, MarketBeat and consolidated U.S. market data. Market-value changes and peak-value gaps are estimates using the current implied share count; rounding may create small differences.
Market snapshot: August 26, 2026, 19:34 EDT (August 27, 01:34 CEST). Prices after the U.S. regular close.
The regular decline erased an estimated $940m. Late trading recovered about $454m, leaving roughly $486m below Tuesday's value.
Implied after-hours market value divided by management's above-$4bn year-end AI Cloud ARR target.
About 85% of the target ARR is under contract. Weighted average term: roughly four years.
Customer prepayments cover about 45% of associated GPU capital spending.
| Provider | Revenue | EPS |
|---|---|---|
| MarketBeat | $132.00m | −$0.55 |
| Zacks preview | $138.89m | −$0.80 |
These are separate provider forecasts, not a blended consensus. Results: August 27. Call: 5:00 p.m. EDT.
| Metric | Q3 FY26 | Q2 FY26 | Seq. |
|---|---|---|---|
| Revenue | $144.8m | $184.7m | −21.6% |
| Adjusted EBITDA | $59.5m | $75.3m | −21.0% |
| Net income/(loss) | −$247.8m | −$155.4m | Wider loss |
Quarter ended March 31, 2026. Lower Bitcoin prices and mining-hardware retirements weighed on results.
| Company | Close | Move | Value | Volume |
|---|---|---|---|---|
| IREN | $39.58 | −6.23% | $14.15bn | 37.45m |
| CoreWeave | $88.01 | −0.03% | $48.54bn | 12.13m |
| Nebius | $213.93 | −3.62% | $58.16bn | 9.17m |
August 26 U.S. regular close. Source: Yahoo Finance.
Average target across 21 analysts tracked by MarketBeat.
| Low | $46 |
| Average | $83 |
| High | $105 |
Pre-results snapshot. Targets can change rapidly after earnings.
| Risk | Transmission to investors | Watch point |
|---|---|---|
| Delivery delay | Pushes contracted ARR recognition outward | Energization and GPU-install dates |
| Capital intensity | Raises financing or dilution risk | Capex, prepayments and unrestricted cash |
| Customer concentration | Increases renewal and counterparty sensitivity | New contract mix |
| Mining volatility | Obscures the AI Cloud transition | Bitcoin economics and retired capacity |
Sources: IREN filings and releases, Yahoo Finance, MarketBeat and Zacks. Market-value changes are estimates derived from Yahoo's August 26 closing price and market capitalization. Figures may differ because of rounding and after-hours liquidity.
Regular close: August 26 at 16:00:01 EDT. After-hours quote: 18:03:50 EDT. Total gain from the prior close: 5.65%.
From the after-hours price, the options upper bound offered 6.2% upside. The lower bound represented 13.1% downside. The skew shows how Wednesday’s late rally consumed much of the bullish move.
Recent options signal published August 24, 2026; range recalculated from the August 26 closing price.
| Metric | Expectation / guide | Change |
|---|---|---|
| Revenue consensus | $2.71B | ≈+35% YoY |
| Adjusted EPS consensus | $0.93 | +38.8% YoY |
| Company revenue guide | $2.70B ±5% | +11.7% QoQ midpoint |
| Adjusted EPS guide | $0.93 ±$0.05 | $0.88–$0.98 |
| Non-GAAP gross margin | 58.25%–59.25% | 58.9% in Q1 |
| Diluted share count | 915M expected | Company guide |
Fiscal Q1 revenue was a record $2.418 billion. Non-GAAP net income reached $718 million, while operating cash flow hit a record $638.8 million.
| Measure | Value | Read-through |
|---|---|---|
| Trailing P/E | 84.2× | Premium leaves little room for a weak guide |
| Closing market cap / Q2 revenue | 81.3× | One quarter, not an annual multiple |
| Annualized Q2 price/sales | ≈20.3× | Assumes the quarter repeats |
| Yahoo one-year target | $266.36 | +4.9% from after-hours price |
| Susquehanna target | $265 | Positive; +4.3% from after hours |
| Rosenblatt target | $300 | Buy; +18.1% from after hours |
Price, P/E and consensus-target snapshot: August 26, 2026, 18:03:50 EDT. Fresh brokerage targets were reported August 25.
Google can buy the warrant shares at $206.58. Most vest only when product-purchase thresholds are met through fiscal 2033. Dilution is therefore tied to sales conversion.
| Company | Session move | Trailing P/E |
|---|---|---|
| Marvell | +1.97% | 84.2× |
| Nvidia | −1.52% | 31.9× |
| Broadcom | −0.33% | 97.6× |
| AMD | +0.36% | 123.6× |
Marvell sits between Nvidia and higher-multiple custom-compute peers. Its earnings must validate optical-networking growth and the custom-silicon pipeline.
Peer close data retrieved August 26, 2026, 17:52 EDT.
Expectations: An in-line quarter may not support the multiple.
Margin: Memory and optical-component costs can compress profitability.
Execution: Custom silicon ramps require long design and qualification cycles.
Dilution: Google warrants equal 6.4% of guided diluted shares.
Tape: Regular volume was only 39% of the three-month average.
Fiscal Q2 2027 results and conference call — August 27, 2026, 16:45 EDT. The market will compare any guidance raise with a $228 billion implied after-hours valuation and the 10% options move.
Sources: Yahoo Finance · Marvell Q1 results · Marvell event notice · Investopedia · Reuters
| Metric | Actual | Consensus | Beat |
|---|---|---|---|
| Revenue | $757.1M | $738.3M | +$18.8M |
| Adjusted EPS | $0.60 | $0.49 | +$0.11 |
| Metric | Q4 FY26 | Q4 FY25 | Change |
|---|---|---|---|
| Revenue | $757.1M | $653.3M | +16% |
| ARR | $2.55B | $2.20B | +16% |
| Adj. gross margin | 87.7% | 88.3% | −60 bps |
| Adj. operating margin | 26.2% | 18.3% | +790 bps |
| Free cash flow | $277.6M | $207.8M | +34% |
Revenue exceeded consensus by 2.5%. Adjusted operating margin expanded 790 basis points. ARR kept pace with quarterly revenue at 16% growth. Fiscal-2027 guidance preserved double-digit sales growth while keeping adjusted operating margin near one quarter of revenue.
Adjusted gross margin fell 60 basis points. Server supply constraints can delay deployments and cash collection. The after-hours price already exceeds the pre-report average analyst target. Extended-hours liquidity can exaggerate moves.
| Metric | Prior | New | Midpoint change |
|---|---|---|---|
| FY2026 revenue | $9.63B–$9.71B | $9.69B–$9.74B | +$45M · +0.47% |
| FY2026 adjusted EPS | $14.72–$14.80 | $15.04–$15.10 | +$0.31 · +2.1% |
| Q4 revenue | — | $2.53B–$2.58B | New range |
| Q4 adjusted EPS | — | $4.10–$4.16 | New range |
| FY2026 free cash flow | — | ~$2.60B | 26.8% of revenue midpoint |
| Measure | Value | Signal |
|---|---|---|
| Adjusted EPS | $2.22 | +6.2% vs est. |
| Q2 gross margin | 75.0% | Flat QoQ |
| Q3 gross margin | 74.0% | -1.0 pt |
| Free cash flow | $21.34B | -56% QoQ |
| DSO | 60 days | +15 days |
| Metric | Q2 FY27 | Sequential | Why it matters |
|---|---|---|---|
| Data Center | $89.0B | +18% | Core demand remains strong |
| ACIE | $40.3B | +25% | Faster than hyperscale |
| Receivables | $63.1B | DSO 45→60 | Cash conversion slowed |
| Inventory | $31.6B | +22% | Rubin launch build |
| Operating cash flow | $24.1B | -52% | Working capital and taxes |
Bull: $108B revenue converts to cashBull: ACIE sustains 25% QoQ growthBear: margin falls below 73.5%Bear: DSO extends againBear: customer guarantees activate
Commitments are future obligations, not immediate debt. Guarantees are contingent. The valuation test is whether Nvidia's revenue and free cash flow scale faster than supply, lease and customer-support exposure.
Information gain: the day’s $4.13 decline erased roughly $530 million of quoted equity value. The unlocked block itself was worth about $1.68 billion at $16.25.
GENB rose 26.4% from Aug. 21 through Aug. 25, then gave back nearly the entire advance. It remained 1.6% above the $16 IPO price at 15:06 EDT on Aug. 26.
| Metric | Latest | Investor read |
|---|---|---|
| Cash + securities | $457.4M | 21.9% of market cap |
| H1 operating cash use | $138.3M | Runway into H1 2028 |
| Q2 collaboration revenue | $6.3M | −37.7% year over year |
| Q2 net loss | $67.3M | Widened from $56.7M |
| Q2 GB-0895 external R&D | $20.5M | +54.3% year over year |
What changes next: ownership supply drove this session. September data can shift the focus back to GB-0895’s pharmacology and the twice-yearly dosing case.
As of Aug. 26, 2026. Morgan Stanley reiterated Buy with a $22 target on Aug. 17; Piper Sandler reiterated Buy with a $24 target on Aug. 7.
Bull case: little actual lock-up selling would make the 20% drop look like a temporary supply discount. Positive COPD data could strengthen the six-month dosing proposition ahead of larger severe-asthma readouts.
Risk case: sustained insider or venture-holder sales could cap rebounds. Weak September pharmacology, faster cash use, or Phase 3 delays would raise financing and dilution risk before commercialization.
Flagship SUV return meets a low-margin growth plan.
Market data: August 26, 2026, 15:30 JST · Dashboard: August 27, 2026, 03:42 JST
Equity-value change uses the ¥9.20 share gain and 1.34 billion shares outstanding.
| Signal | Verified measure |
|---|---|
| Global return | After 5 years |
| Lifetime sales | >3.25M units |
| Historical markets | >170 |
| Dakar record | 12 wins |
| Platform | Triton ladder frame |
| Drive control | S-AWC |
Lifetime Pajero sales equal 3.8 times Mitsubishi's current full-year volume target.
Reveal date and triple multi meter confirmed.
Pricing, powertrain and initial markets are key.
Management links Pajero to sales growth.
857,000 retail units and 2.8% margin.
Sources: Mitsubishi Motors official Pajero site and releases; Mitsubishi Motors Q1 presentation summary; StockAnalysis and Investing.com market and consensus data. Currency is Japanese yen. Estimates are explicitly marked.
Rasonque is now a first-in-class, once-daily oral RAS inhibitor for certain adults with metastatic pancreatic cancer.
| Metric | Amount | Ratio to market cap |
|---|---|---|
| Quoted market value | $45.65B | 100% |
| Cash and securities, June 30 | $3.94B | 8.6% |
| 2026 operating-expense midpoint | $2.15B | 4.7% |
| Q2 operating expenses | $505.1M | 1.1% |
| Q2 net loss | $644.4M | 1.4% |
Pricing remains unknown. Slow coverage decisions can defer revenue even after approval.
Manufacturing limits or weak real-world uptake would pressure launch estimates.
The average analyst target offers only 4.6% upside. Failed expansion trials would narrow the revenue base.
Approval creates the first direct sales channel for Revolution Medicines. The financial test is whether Rasonque’s launch and later-label expansion can grow into a $45.65 billion valuation while annual operating expenses run near $2.15 billion.
| Fiscal Q3 2026 | Value | YoY |
|---|---|---|
| Revenue | $109.4B | +16% |
| Net income | $29.8B | +27% |
| Diluted EPS | $2.02 | +29% |
| Gross margin | 50.1% | +3.6 pts |
| Mac revenue | $10.4B | +28.7% |
Gross margin included an approximately two-point tariff-refund benefit.
Apple gives no Mac mini unit or revenue forecast. Higher prices may weaken demand. Memory constraints can delay shipments or pressure margins. Product claims are based on Apple's controlled tests.
| Metric | Value | YoY |
|---|---|---|
| Group revenue | 191.1M zł | +6% |
| Witcher IP revenue | 44.7M zł | +36% |
| Witcher share of sales | 23.4% | +5.2 pts |
| Net profit | 106.2M zł | −5% |
| Cash/deposits/bonds | 1.41B zł | +6% q/q |
| Signal | Reading |
|---|---|
| Market cap | 24.01B zł |
| Quoted value lost today | ≈199.8M zł |
| Trailing P/E | 39.41× |
| 52-week range | 211.30–297.00 zł |
| Shares outstanding | 99.91M |
| Erste view | Meaningful positive Q4 impact |
| Driver | Upside | Constraint |
|---|---|---|
| Free remaster | Reactivates a 65M-player catalogue | No upgrade revenue from existing owners |
| New platforms | Incremental unit sales and distribution | Platform royalties and launch costs |
| Paid 2027 expansion | Monetizes a larger installed base | Pricing and release date undisclosed |
| 2028 Witcher 4 target | Extends franchise roadmap | Long flagship-release gap |
The 70–75 million-copy figure is an analyst estimate. A free update can lift engagement without converting into enough new purchases or expansion sales.
Sources: CD Projekt announcement and Q1 2026 presentation; Reuters, Aug. 26, 2026; Google Finance at 15:23:28 CEST. Time-sensitive figures are timestamped above.
| Metric | Q2 2026 | YoY |
|---|---|---|
| Total sales | $5.442B | +7.5% |
| Cardiovascular | $3.624B | +8.3% |
| MedSurg | $1.818B | +5.9% |
| Adjusted EPS | $0.86 | +14.7% |
| GAAP net income | $907M | +13.8% |
| Signal | Current reading |
|---|---|
| FY26 sales growth | 5.5%–6.5% reported |
| FY26 adjusted EPS | $3.28–$3.32 |
| Q3 adjusted EPS | $0.80–$0.82 |
| P/E | 19.38× |
| Analyst consensus | Buy · 31 analysts |
| Average target | $62.69 · 31% upside |
| Recovery path | Revenue effect | Investor implication |
|---|---|---|
| Faster than Stryker | Below $316M | More orders may shift within the quarter rather than disappear. |
| About three weeks | $316M–$369M | Evercore's 600–700 bp scenario; a guide cut becomes plausible. |
| Longer or broader | Above $369M | Margin pressure and customer disruption could outlast shipment delays. |
Boston Scientific has not determined whether the incident is reasonably likely to be material. The full scope, recovery duration and any data loss remain unknown.
Sources: Boston Scientific Q2 2026 results; Reuters, Aug. 26, 2026; Google Finance quote at 09:40:21 EDT; StockAnalysis analyst consensus. The $316M–$369M range is a scenario calculation, not company guidance.
Good Good Quantum Triple Diamond Max, 460cc head, adjustable 10g weight.
| Metric | Result |
|---|---|
| Revenue | $430.3M · +4.5% |
| Operating income | $100.3M · +31.6% |
| Operating margin | 23.3% · +480 bp |
| Share of group sales | 70.3% |
| Metric | Result |
|---|---|
| Q2 sales | $612.2M · +2.0% |
| GAAP gross margin | 50.1% · +620 bp |
| FY26 sales guide | $2.045B–$2.070B |
| FY26 adjusted EBITDA | $246M–$260M |
| Average target | $20.50 |
| Implied upside from $15.47 | 32.5% |
| Coverage | 11 analysts |
| Rating mix | 5 Strong Buy · 5 Hold · 1 Sell |
Contained case: investigations close without retailer, media or partner withdrawals; the 0.58% premarket rebound persists. Adverse case: partner action raises campaign costs or weakens demand in a segment producing 70.3% of quarterly sales. Watch the product listing, PGA Tour decisions and management's next equipment-sales commentary.
| Units | Standard | Ultimate |
|---|---|---|
| 10M | $0.80B | $1.00B |
| 25M | $2.00B | $2.50B |
| 50M | $4.00B | $5.00B |
| Buy / Hold / Sell | 27 / 0 / 1 |
| Average target | $286.89 |
| Implied upside | 23.2% |
| Low / High | $170 / $368 |
| FY26 | Revenue | Gross margin | Net income |
|---|---|---|---|
| Q1 | $5.0B | 9.3% | $168M |
| Q2 | $12.7B | 6.3% | $401M |
| Q3 | $10.2B | 9.9% | $483M |
| Q4 | $11.1B | 17.5% | $1.18B |
| Company | Close | Daily move | Signal |
|---|---|---|---|
| Super Micro (SMCI) | $38.46 | +9.35% | Cisco channel |
| Dell (DELL) | $451.50 | +4.23% | Server peer |
| HPE (HPE) | $53.44 | +1.93% | Server peer |
| Cisco (CSCO) | $111.11 | +0.80% | Platform owner |
